Amgen’s AMG-162 for treatment of osteoporosis can be a blockbuster by 2013 Decision Assets, Inc., forecasts that Amgen’s novel biological agent for the treating osteoporosis, AMG-162, can be a blockbuster by 2013. Premium prices of AMG-162 shall propel the sales of this agent ventolin-spray.com/doses-and-uses.htm . The new Pharmacor research entitled Osteoporosis also discovers that the full total osteoporosis marketplace – – including osteopenia – – will increase at a 4.6 percent annual rate. Elements that may drive the market’s growth include substantial boosts in the drug-treated patient population and the start of new agents that require less-frequent administration and provide novel mechanisms of action. Related StoriesNew protein supplement lowers cholesterol, prevents osteoporosisElderly women should take even more vitamin D supplementation through the wintertime, suggests researchersTARSA Therapeutics' TBRIA NDA approved by FDA for review Much of the development will be because of the launch of brand-new bisphosphonates, including Roche’s Boniva/Bonviva , Novartis’s Zometa , and Amgen’s novel biological agent, the RANKL inhibitor AMG – 162, stated Donny Wong, Ph.D., analyst at Decision Assets.
Amgen’s Prolia receives FDA authorization for new indications to treat cancer patients Amgen today announced that the U.S. Aromatase inhibitors tend to be found in patients with breasts cancer to prevent recurrence of disease, and androgen deprivation therapy is definitely often used in patients with prostate cancer to prevent or control recurrent disease. These remedies reduce hormone levels, resulting in bone loss and an increased risk of fracture. ‘Bone reduction and fractures are acknowledged adverse effects of hormone ablation therapies but we have not had an approved treatment option to prevent these problems for our individuals,’ said Matthew Smith, M.D., Ph.D., director of the Genitourinary Malignancies Plan at Massachusetts General Hospital Cancer Middle, Boston.